Anchor Investment Management LLC Trims Stock Position in Bristol Myers Squibb Company $BMY

Anchor Investment Management LLC lessened its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 14.2% during the 1st quarter, Holdings Channel reports. The institutional investor owned 12,431 shares of the biopharmaceutical company’s stock after selling 2,055 shares during the quarter. Anchor Investment Management LLC’s holdings in Bristol Myers Squibb were worth $758,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in BMY. Brighton Jones LLC increased its holdings in Bristol Myers Squibb by 33.4% in the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock valued at $1,116,000 after purchasing an additional 4,935 shares during the last quarter. Bank Pictet & Cie Europe AG acquired a new stake in Bristol Myers Squibb in the 4th quarter valued at approximately $13,094,000. Nuveen Asset Management LLC increased its holdings in Bristol Myers Squibb by 16.1% in the 4th quarter. Nuveen Asset Management LLC now owns 10,420,945 shares of the biopharmaceutical company’s stock valued at $589,409,000 after purchasing an additional 1,444,822 shares during the last quarter. NorthRock Partners LLC increased its holdings in Bristol Myers Squibb by 192.8% in the 4th quarter. NorthRock Partners LLC now owns 26,839 shares of the biopharmaceutical company’s stock valued at $1,518,000 after purchasing an additional 17,672 shares during the last quarter. Finally, Nearwater Capital Markets Ltd acquired a new stake in Bristol Myers Squibb in the 4th quarter valued at approximately $15,837,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Insiders Place Their Bets

In related news, EVP David V. Elkins sold 56,000 shares of the business’s stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total value of $2,650,480.00. Following the completion of the sale, the executive vice president directly owned 167,379 shares of the company’s stock, valued at $7,922,048.07. The trade was a 25.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.09% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms have commented on BMY. Daiwa America downgraded shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 5th. Morgan Stanley restated a “hold” rating on shares of Bristol Myers Squibb in a research note on Thursday, July 31st. Wall Street Zen downgraded shares of Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 6th. Daiwa Capital Markets downgraded shares of Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price target for the company. in a research note on Tuesday, August 5th. Finally, Citigroup lowered their target price on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a “neutral” rating for the company in a research note on Friday, August 1st. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fifteen have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Bristol Myers Squibb currently has a consensus rating of “Hold” and an average target price of $56.38.

Bristol Myers Squibb Stock Performance

Shares of BMY stock opened at $47.15 on Thursday. The company has a current ratio of 1.21, a quick ratio of 1.11 and a debt-to-equity ratio of 2.54. The firm has a fifty day moving average price of $47.08 and a 200 day moving average price of $50.33. The company has a market cap of $95.97 billion, a P/E ratio of 19.01, a PEG ratio of 2.42 and a beta of 0.35. Bristol Myers Squibb Company has a 12 month low of $42.96 and a 12 month high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, topping analysts’ consensus estimates of $1.07 by $0.39. The firm had revenue of $12.27 billion during the quarter, compared to the consensus estimate of $11.32 billion. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The company’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.07 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. Sell-side analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, August 1st. Investors of record on Thursday, July 3rd were given a $0.62 dividend. The ex-dividend date of this dividend was Thursday, July 3rd. This represents a $2.48 dividend on an annualized basis and a yield of 5.3%. Bristol Myers Squibb’s payout ratio is 100.00%.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.